Abstract
Monoclonal antibodies (mAbs) constitute a promising class of therapeutics, since ca. 25% of all biotech drugs in development are mAbs. Even though their therapeutic value is now well established, human- and murine-derived mAbs do have deficiencies, such as short in vivo lifespan and low stability. However, the most difficult obstacle to overcome, toward the exploitation of mAbs for disease treatment, is the prevention of the formation of protein aggregates. ANTISOMA is a pipeline for the reduction of the aggregation tendency of mAbs through the decrease in their intrinsic aggregation propensity, based on an automated amino acid substitution approach. The method takes into consideration the special features of mAbs and aims at proposing specific point mutations that could lead to the redesign of those promising therapeutics, without affecting their epitope-binding ability. The method is available online at http://bioinformatics.biol.uoa.gr/ANTISOMA.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
Abbreviations
- APRs:
-
Aggregation-prone regions
- CDRs:
-
Complementarity determining regions
- FDA:
-
US Food and Drug Administration
- mAbs:
-
Monoclonal antibodies
References
Andya JD, Hsu CC, Shire SJ (2003) Mechanisms of aggregate formation and carbohydrate excipient stabilization of lyophilized humanized monoclonal antibody formulations. AAPS PharmSci 5(2):E10. https://doi.org/10.1208/ps050210
Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE (2000) The Protein Data Bank. Nucleic Acids Res 28(1):235–242
Bruno V, Battaglia G, Nicoletti F (2011) The advent of monoclonal antibodies in the treatment of chronic autoimmune diseases. Neurol Sci 31(Suppl 3):283–288. https://doi.org/10.1007/s10072-010-0382-6
Chothia C, Lesk AM (1987) Canonical structures for the hypervariable regions of immunoglobulins. J Mol Biol 196(4):901–917
Cromwell ME, Hilario E, Jacobson F (2006) Protein aggregation and bioprocessing. AAPS J 8(3):E572. https://doi.org/10.1208/aapsj080366
Cui Y, Cui P, Chen B, Li S, Guan H (2017) Monoclonal antibodies: formulations of marketed products and recent advances in novel delivery system. Drug Dev Ind Pharm 43(4):519–530. https://doi.org/10.1080/03639045.2017.1278768
Daugherty AL, Mrsny RJ (2006) Formulation and delivery issues for monoclonal antibody therapeutics. Adv Drug Deliv Rev 58(5–6):686–706. https://doi.org/10.1016/j.addr.2006.03.011
De Baets G, Van Durme J, van der Kant R, Schymkowitz J, Rousseau F (2015) Solubis: optimize your protein. Bioinformatics 31(15):2580–2582. https://doi.org/10.1093/bioinformatics/btv162
de Groot NS, Castillo V, Grana-Montes R, Ventura S (2012) AGGRESCAN: method, application, and perspectives for drug design. Methods Mol Biol 819:199–220. https://doi.org/10.1007/978-1-61779-465-0_14
Dudgeon K, Rouet R, Kokmeijer I, Schofield P, Stolp J, Langley D, Stock D, Christ D (2012) General strategy for the generation of human antibody variable domains with increased aggregation resistance. Proc Natl Acad Sci U S A 109(27):10879–10884. https://doi.org/10.1073/pnas.1202866109
Eswar N, Webb B, Marti-Renom MA, Madhusudhan MS, Eramian D, Shen MY, Pieper U, Sali A (2007) Comparative protein structure modeling using MODELLER. Curr Protoc Protein Sci 50(1):2.9.1–2.9.31. https://doi.org/10.1002/0471140864.ps0209s50
Fernandez-Escamilla AM, Rousseau F, Schymkowitz J, Serrano L (2004) Prediction of sequence-dependent and mutational effects on the aggregation of peptides and proteins. Nat Biotechnol 22(10):1302–1306. https://doi.org/10.1038/nbt1012
Hamodrakas SJ (2011) Protein aggregation and amyloid fibril formation prediction software from primary sequence: towards controlling the formation of bacterial inclusion bodies. FEBS J 278(14):2428–2435. https://doi.org/10.1111/j.1742-4658.2011.08164.x
Hanson RM, Prilusky J, Renjian Z, Nakane T, Sussman JL (2013) JSmol and the next-generation web-based representation of 3D molecular structure as applied to Proteopedia. Israel J Chem 53(3–4):207–216. https://doi.org/10.1002/ijch.201300024
Johnson G, Wu TT (2000) Kabat database and its applications: 30 years after the first variability plot. Nucleic Acids Res 28(1):214–218
Kabsch W, Sander C (1983) Dictionary of protein secondary structure: pattern recognition of hydrogen-bonded and geometrical features. Biopolymers 22(12):2577–2637. https://doi.org/10.1002/bip.360221211
Kohler G, Milstein C (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256(5517):495–497
Lawrence MS, Phillips KJ, Liu DR (2007) Supercharging proteins can impart unusual resilience. J Am Chem Soc 129(33):10110–10112. https://doi.org/10.1021/ja071641y
Leem J, Dunbar J, Georges G, Shi J, Deane CM (2016) ABodyBuilder: automated antibody structure prediction with data-driven accuracy estimation. MAbs 8(7):1259–1268. https://doi.org/10.1080/19420862.2016.1205773
Lefranc MP, Giudicelli V, Duroux P, Jabado-Michaloud J, Folch G, Aouinti S, Carillon E, Duvergey H, Houles A, Paysan-Lafosse T, Hadi-Saljoqi S, Sasorith S, Lefranc G, Kossida S (2015) IMGT(R), the international ImMunoGeneTics information system(R) 25 years on. Nucleic Acids Res 43(Database issue):D413–D422. https://doi.org/10.1093/nar/gku1056
MacCallum RM, Martin AC, Thornton JM (1996) Antibody-antigen interactions: contact analysis and binding site topography. J Mol Biol 262(5):732–745. https://doi.org/10.1006/jmbi.1996.0548
Modjtahedi H, Ali S, Essapen S (2012) Therapeutic application of monoclonal antibodies in cancer: advances and challenges. Br Med Bull 104:41–59. https://doi.org/10.1093/bmb/lds032
Nicoud L, Jagielski J, Pfister D, Lazzari S, Massant J, Lattuada M, Morbidelli M (2016) Kinetics of monoclonal antibody aggregation from dilute toward concentrated conditions. J Phys Chem B 120(13):3267–3280. https://doi.org/10.1021/acs.jpcb.5b11791
Nuttall SD, Irving RA, Hudson PJ (2000) Immunoglobulin VH domains and beyond: design and selection of single-domain binding and targeting reagents. Curr Pharm Biotechnol 1(3):253–263
Roberts CJ (2014) Therapeutic protein aggregation: mechanisms, design, and control. Trends Biotechnol 32(7):372–380. https://doi.org/10.1016/j.tibtech.2014.05.005
Rousseau F, Serrano L, Schymkowitz JW (2006) How evolutionary pressure against protein aggregation shaped chaperone specificity. J Mol Biol 355(5):1037–1047. https://doi.org/10.1016/j.jmb.2005.11.035
Sanchez de Groot N, Pallares I, Aviles FX, Vendrell J, Ventura S (2005) Prediction of “hot spots” of aggregation in disease-linked polypeptides. BMC Struct Biol 5:18. https://doi.org/10.1186/1472-6807-5-18
Schymkowitz J, Borg J, Stricher F, Nys R, Rousseau F, Serrano L (2005) The FoldX web server: an online force field. Nucleic Acids Res 33(Web Server):W382–W388. https://doi.org/10.1093/nar/gki387
Tramontano A, Chothia C, Lesk AM (1990) Framework residue 71 is a major determinant of the position and conformation of the second hypervariable region in the VH domains of immunoglobulins. J Mol Biol 215(1):175–182. https://doi.org/10.1016/S0022-2836(05)80102-0
Tsolis AC, Papandreou NC, Iconomidou VA, Hamodrakas SJ (2013) A consensus method for the prediction of ‘aggregation-prone’ peptides in globular proteins. PLoS One 8(1):e54175. https://doi.org/10.1371/journal.pone.0054175
Uchiyama S (2014) Liquid formulation for antibody drugs. Biochim Biophys Acta 1844(11):2041–2052. https://doi.org/10.1016/j.bbapap.2014.07.016
van der Kant R, Karow-Zwick AR, Van Durme J, Blech M, Gallardo R, Seeliger D, Assfalg K, Baatsen P, Compernolle G, Gils A, Studts JM, Schulz P, Garidel P, Schymkowitz J, Rousseau F (2017) Prediction and reduction of the aggregation of monoclonal antibodies. J Mol Biol S0022-2836(17):30118–30113. https://doi.org/10.1016/j.jmb.2017.03.014
Weitzner BD, Jeliazkov JR, Lyskov S, Marze N, Kuroda D, Frick R, Adolf-Bryfogle J, Biswas N, Dunbrack RL Jr, Gray JJ (2017) Modeling and docking of antibody structures with Rosetta. Nat Protoc 12(2):401–416. https://doi.org/10.1038/nprot.2016.180
Wu TT, Kabat EA (1970) An analysis of the sequences of the variable regions of Bence Jones proteins and myeloma light chains and their implications for antibody complementarity. J Exp Med 132(2):211–250
Yamashita K, Ikeda K, Amada K, Liang S, Tsuchiya Y, Nakamura H, Shirai H, Standley DM (2014) Kotai antibody builder: automated high-resolution structural modeling of antibodies. Bioinformatics 30(22):3279–3280. https://doi.org/10.1093/bioinformatics/btu510
Zambrano R, Jamroz M, Szczasiuk A, Pujols J, Kmiecik S, Ventura S (2015) AGGRESCAN3D (A3D): server for prediction of aggregation properties of protein structures. Nucleic Acids Res 43(W1):W306–W313. https://doi.org/10.1093/nar/gkv359
Zhang A, Singh SK, Shirts MR, Kumar S, Fernandez EJ (2012) Distinct aggregation mechanisms of monoclonal antibody under thermal and freeze-thaw stresses revealed by hydrogen exchange. Pharm Res 29(1):236–250. https://doi.org/10.1007/s11095-011-0538-y
Acknowledgments
This work has been partly supported by the University of Piraeus Research Center.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this paper
Cite this paper
Nastou, K.C. et al. (2020). ANTISOMA: A Computational Pipeline for the Reduction of the Aggregation Propensity of Monoclonal Antibodies. In: Vlamos, P. (eds) GeNeDis 2018. Advances in Experimental Medicine and Biology, vol 1194. Springer, Cham. https://doi.org/10.1007/978-3-030-32622-7_34
Download citation
DOI: https://doi.org/10.1007/978-3-030-32622-7_34
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-32621-0
Online ISBN: 978-3-030-32622-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)